The Case is Made for New CPT Codes

The Challenge

The Challenge

A ground-breaking medical device, although recognized by major clinical compendia, was lacking the appropriate Current Procedural Terminology (CPT) codes. This created hesitancy among providers, who feared they would not be reimbursed or prescribing this supportive care technology for their patients.

The IP Solution

The IP Solution

IP developed and executed a multi-pronged strategy to support the approval of a CPT code for the medical device.

As a key first step, our team worked closely with the manufacturer to author and submit an article to a peer-reviewed publication. It addressed the importance of the work and direct involvement needed on the part of physicians, to support the use of the device.

Following the publication of the article, our team delivered the guidance and support needed to submit an application to the American Medical Association (AMA) for a new CPT code.

Additionally, we engaged influential physicians and thought leaders within the supportive care space to advocate for the product and create awareness among providers and patients.

IP continues to be critical in our US strategy. From day one they have worked closely with [us] as an extended part of our company, understanding our challenges and working with us to find solutions putting a clear strategy in place and ultimately delivering on their word. Our relationship is incredibly strong.

CEO, Medical Device Company
The Result

The Results

Months of persistence paid off and the AMA accepted the company’s application for a Category III CPT Code, a significant step to ensure access for cancer and chemotherapy patients across the US. IP has continued to provide support in crafting a communication strategy to ensure there is substantial awareness of the new code and reimbursement options for practices across the country.

Related Case Studies

Healthcare policy changes interpreted in real-time

A European-based pharmaceutical company with several products in the US market was under pressure to interpret and respond to rapidly changing US healthcare policies which could potentially impact access for their portfolio of oncology products.

A comprehensive launch strategy leads to broad access

A biopharmaceutical company was in the midst of bringing its first product to market with breakthrough therapy designation. The PDUFA date was fast approaching, and their small team needed guidance to steer them through the complicated access and reimbursement landscape.

Understanding the European Market

A mid-sized pharmaceutical company was looking to enter the European market through a compassionate use/early access pathway but lacked an understanding of the requirements specific to each country that would lead to broad access and reimbursement for their product across Europe.